Home > Publications database > WHO International Standards for antibodies to HPV6 HPV11 HPV31 HPV33 HPV45 HPV52 and HPV58. > print

001     294315
005     20241103013537.0
024 7 _ |a 10.1038/s41541-024-00949-2
|2 doi
024 7 _ |a pmid:39256440
|2 pmid
024 7 _ |a pmc:PMC11387505
|2 pmc
024 7 _ |a altmetric:167418181
|2 altmetric
037 _ _ |a DKFZ-2024-02148
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Kemp, Troy J
|b 0
245 _ _ |a WHO International Standards for antibodies to HPV6 HPV11 HPV31 HPV33 HPV45 HPV52 and HPV58.
260 _ _ |a [London]
|c 2024
|b Nature Publishing Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1730124704_10605
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Previously established World Health Organization (WHO) International Standards (IS) for anti-HPV16 and HPV18 antibodies are used to harmonize results across human papillomavirus (HPV) serology assays. Here, we present an international collaborative study to establish ISs for antibodies against HPV6 (NIBSC code 19/298), HPV11 (20/174), HPV31 (20/176), HPV33 (19/290), HPV45 (20/178), HPV52 (19/296) and HPV58 (19/300). The candidate standards were prepared using sera from naturally infected individuals. Each candidate was shown to be monospecific for reactivity against its indicated HPV type except for the HPV11 candidate, which was also reactive against other types. Expression of antibody levels relative to the relevant candidate IS reduced inter-laboratory variation allowing greater comparability between laboratories. Based on these results, the WHO Expert Committee on Biological Standardization established each of the 7 candidates as the 1st IS for antiserum to its indicated HPV type for use in the standardization of HPV pseudovirion-based neutralization and antibody-binding assays.
536 _ _ |a 314 - Immunologie und Krebs (POF4-314)
|0 G:(DE-HGF)POF4-314
|c POF4-314
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
700 1 _ |a Panicker, Gitika
|b 1
700 1 _ |a Eklund, Carina
|b 2
700 1 _ |a Nie, Jianhui
|b 3
700 1 _ |a Wang, Youchun
|b 4
700 1 _ |a Beddows, Simon
|0 0000-0002-6879-6215
|b 5
700 1 _ |a Rigsby, Peter
|b 6
700 1 _ |a Huang, Weijin
|0 0000-0002-4246-8889
|b 7
700 1 _ |a Dillner, Joakim
|b 8
700 1 _ |a Unger, Elizabeth R
|b 9
700 1 _ |a Pinto, Ligia A
|b 10
700 1 _ |a Wilkinson, Dianna E
|0 0000-0001-6936-8629
|b 11
700 1 _ |a participants, collaborative study
|b 12
|e Collaboration Author
700 1 _ |a Licciardi, Paul
|b 13
|e Contributor
700 1 _ |a Toh, Zheng Quan
|b 14
|e Contributor
700 1 _ |a Müller, Martin
|0 P:(DE-He78)47d2c5b8ee00ab8a0c16e14137427579
|b 15
|e Contributor
|u dkfz
700 1 _ |a Rajanathan, T M Chozhavel
|b 16
|e Contributor
700 1 _ |a Li, Shaowei
|b 17
|e Contributor
700 1 _ |a Xia, Ningshao
|b 18
|e Contributor
700 1 _ |a Liu, Ge
|b 19
|e Contributor
700 1 _ |a Zhou, Chenliang
|b 20
|e Contributor
700 1 _ |a Zhou, Lingyun
|b 21
|e Contributor
700 1 _ |a Xu, Nan
|b 22
|e Contributor
700 1 _ |a Panwar, Kavita
|b 23
|e Contributor
700 1 _ |a Galloway, Denise
|b 24
|e Contributor
700 1 _ |a Carter, Jody
|b 25
|e Contributor
773 _ _ |a 10.1038/s41541-024-00949-2
|g Vol. 9, no. 1, p. 165
|0 PERI:(DE-600)2882262-6
|n 1
|p 165
|t npj vaccines
|v 9
|y 2024
|x 2059-0105
909 C O |o oai:inrepo02.dkfz.de:294315
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)47d2c5b8ee00ab8a0c16e14137427579
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-314
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Immunologie und Krebs
|x 0
914 1 _ |y 2024
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NPJ VACCINES : 2022
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-04-12T15:11:19Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-04-12T15:11:19Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-04-12T15:11:19Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2023-04-12T15:11:19Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-24
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-24
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NPJ VACCINES : 2022
|d 2023-08-24
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-08-24
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-08-24
920 1 _ |0 I:(DE-He78)D335-20160331
|k D335
|l Tumorvirus-spez. Vakzinierungsstrategie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)D335-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21